GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » EV-to-FCF

I-MAB (IMAB) EV-to-FCF : 1.88 (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, I-MAB's Enterprise Value is $-150.38 Mil. I-MAB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-80.12 Mil. Therefore, I-MAB's EV-to-FCF for today is 1.88.

The historical rank and industry rank for I-MAB's EV-to-FCF or its related term are showing as below:

IMAB' s EV-to-FCF Range Over the Past 10 Years
Min: -18.71   Med: 1.1   Max: 74.56
Current: 1.96

During the past 7 years, the highest EV-to-FCF of I-MAB was 74.56. The lowest was -18.71. And the median was 1.10.

IMAB's EV-to-FCF is ranked better than
56.92% of 390 companies
in the Biotechnology industry
Industry Median: 6.305 vs IMAB: 1.96

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-14), I-MAB's stock price is $1.85. I-MAB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.464. Therefore, I-MAB's PE Ratio for today is At Loss.


I-MAB EV-to-FCF Historical Data

The historical data trend for I-MAB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB EV-to-FCF Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - 40.72 -19.90 0.83 0.80

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.90 - 0.83 - 0.80

Competitive Comparison of I-MAB's EV-to-FCF

For the Biotechnology subindustry, I-MAB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where I-MAB's EV-to-FCF falls into.



I-MAB EV-to-FCF Calculation

I-MAB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-150.382/-80.124
=1.88

I-MAB's current Enterprise Value is $-150.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. I-MAB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-80.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

I-MAB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.85/-2.464
=At Loss

I-MAB's share price for today is $1.85.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. I-MAB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.464.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


I-MAB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of I-MAB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.